The test identifies the primary origin of many types of tumors of uncertain or unknown origin and facilitates physicians by confirming suspected origins, or providing possible new origins to explore which can affect treatment options.
miRview mets² provides physicians and patients a wide panel of 42 identifiable tumor origins and biologically motivated proprietary classifiers to effectively direct the diagnostic process.
miRview mets² classifiers includes clinical, biological and molecular knowledge that provides only one or two most likely suspected origins, with the vast majority of cases providing just a single origin or answer.
The assay also identifies sarcomas, lymphomas and other non-epithelial malignancies, as well as more histologic subtypes.
